Medicine
Doxorubicin Hydrochloride Liposome 50 mg/25 mL liposomal injectable suspension
Doxorubicin Hydrochloride Liposome 50 mg/25 mL liposomal injectable suspension is a prescription medicine containing Doxorubicin for intravenous use, marketed by Sagent Pharmaceuticals, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Conditions Refrigerate unopened vials of doxorubicin hydrochloride liposome…
Key facts
- Active ingredient (INN)
- Doxorubicin
- Brand
- Doxorubicin Hydrochloride Liposome
- Strength
- 50 mg/25 mL
- Dosage form
- Liposomal injectable suspension
- Route
- Intravenous
- Packs
- 1 vial of 25 mL
- Marketing authorisation holder
- Sagent Pharmaceuticals
- Manufacturer
- Sagent Pharmaceuticals
- Origin register
- US FDA, United States
- Storage
- Conditions Refrigerate unopened vials of doxorubicin hydrochloride liposome injection at 2° to 8°C (36° to 46°F). Do not freeze.
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- L01DB01 Doxorubicin
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 1 March 2026
- Identifiers
- RxCUI 1790115, 1790127DailyMed set ID c8eb4784-36e0-483f-9e5d-af0552e49bb5NDC 25021-263Application ANDA219881
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 vial in 1 carton / 25 mL in 1 vial | 25021-263-25 | Sagent Pharmaceuticals | 1 March 2026 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Doxorubicin 50 mg/25 mL liposomal injectable suspension.
- Doxorubicin 50 mg/25 mL liposomal injectable suspensionAvailable on request—US FDA7 packs Cold chain
- Doxil 50 mg/25 mL liposomal injectable suspensionAvailable on requestBaxter HealthcareUS FDA1 pack Cold chain
- Doxil 50 mg/25 mL liposomal injectable suspensionAvailable on requestBaxter HealthcareUS FDA1 pack Cold chain
- Doxorubicin 50 mg/25 mL liposomal injectable suspensionAvailable on request—US FDA1 pack Cold chain
Other strengths and forms of Doxorubicin
Clinical summary
Doxorubicin is an anthracycline topoisomerase inhibitor indicated as a component of multi-agent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer, among other approved uses. MedsAcross supplies Doxorubicin for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about DoxorubicinFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Doxorubicin Hydrochloride prescribing information (Pfizer Laboratories) · U.S. National Library of Medicine, DailyMed
- Caelyx pegylated liposomal: European public assessment report (EPAR) · European Medicines Agency
- Myocet liposomal (previously Myocet): European public assessment report (EPAR) · European Medicines Agency
Need Doxorubicin Hydrochloride Liposome 50 mg/25 mL liposomal injectable suspension for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.